[1] Basi A, Khaledi F, Karbalaie Niya MH, Rezvani H, Rakhshani N. Epidermal growth factor receptor mutations in lung adenocarcinomas: A single center study from Iran. Asian Pac J Cancer Prev. 2018;19(1):111. [DOI: 10.22034/APJCP.2018. 19.1.111] [PMID] [PMCID]
[2] Siegel RL, Miller KD, Fuchs HE, J Ahmedin. Cancer statistics, 2021. CA: Cancer J Clin. 71(1):7-33. [DOI: 10.3322/caac.21654 ] [PMID] [3] Ng KS, Sun CK, Ting KB, Kun AY. Prognostic factors of EGFR -mutated metastatic adenocarcinoma of lung. Eur J Radiol. 2020;123:108780. [DOI: 10.1016/j.ejrad.2019.108780] [4] Bozorgmehr F, Kazdal D, Chung I, Kirchner M, Magios N, Kriegsmann M, Allgaeuer M, Klotz LV, Muley T, El Shafie RA, Fischer JR. De Novo Versus Secondary Metastatic EGFR -Mutated Non-Small-Cell Lung Cancer. Frontiers in Oncology. 2021;11:640048. [DOI: 10.3389/fonc.2021.640048] [5] Deng C, Zhang Y, Ma Z, Fu F, Deng L, Li Y, et al. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2021;162(3): 664-674.e7. [DOI: 10.1016/j.jtcvs.2020.05.099]
[6] Mohammadzadeh S, Jowkar Z, Mirzai M, Geramizadeh B. Epidermal Growth Factor Receptor (EGFR) Gene Mutation Analysis in Adenocarcinoma of Lung, the First Report from Iran. Iran J Pathol. 2019; 14(1):1. [DOI: 10.30699/IJP.14.1.1] [PMID] [PMCID]
[7] Basiri R, Hossein Jafarian A, Karimi M, Mohammadzadeh Lari S, Haghgoo SM. Expression of epidermal growth factor receptor and the association with demographic and prognostic factors in patients with non-small cell lung cancer. J Cardiothorac Med. 2015; 3(2):297-302. [DOI: 10.22038/jctm.2015.4377]
[8] Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, et al. Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. Chemotherapy.2011; 57(2):108-14. [DOI:10. 1159/000321490] [PMID]
[9] Zhang SM, Zhu QG, Ding XX, Lin S, Zhao J, Guan L, et al. Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis. Cancer Manag Res. 2018; 10:3393. [DOI: 10.2147/CMAR.S167578] [PMID] [PMCID]
[10] Haghgoo SM, Khosravi A, Mortaz E, Pourabdollah-Toutkaboni M, Seifi S, Sabour S, et al. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients. Clin Biochem.2017; 50(6):293-300. [DOI: 10.1016/j.clinbiochem. 2016.11.033] [PMID] [11] Isaka T, Ito H, Yokose T, Saito H, Adachi H, Murakami K, et al. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status. BMC Cancer. 2022;22(1):966. [DOI: 10.1186/s12885-022-10057-w] [PMID] [PMCID]
[12] Nakra T, Singh V, Nambirajan A, Malik PS, Mohan A, Jain D. Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non–small cell lung carcinoma. J Pathol Transl Med.2021; 55(4):279. [DOI: 10.4132/jptm.2021.05.10] [PMID] [PMCID]
[13] Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinico-
pathological predictors of EGFR /KRAS mutational status in primary lung adenocarcinomas. Mod Pathol.2010; 23(2): 159-68. [DOI: 10.1038/modpathol.2009.154] [PMID]
[14] Önal Ö, Koçer M, Eroğlu HN, Yilmaz SD, Eroğlu I, Karadoğan D. Survival analysis and factors affecting survival in patients who presented to the medical oncology unit with non-small cell lung cancer. Turk J Med Sci.2020, 50(8):1838-50. [DOI:10. 3906/sag-1912-205] [PMID] [PMCID
)